Complement C1 inhibitor protein - CSL Behring

Drug Profile

Complement C1 inhibitor protein - CSL Behring

Alternative Names: Berinert; Berinert HS; Berinert P; C1 esterase inhibitor - CSL Behring; C1 esterase inhibitor concentrate; C1-INH - CSL Behring; CE 1145; Complement C1 inactivator - CSL Behring; CSL 830; Haegarda; Human C1 esterase inhibitor concentrate

Latest Information Update: 17 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CSL Behring
  • Class Complement C1 inactivator proteins; Vascular disorder therapies
  • Mechanism of Action Complement C1s inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hereditary angioedema; Angioedema
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hereditary angioedema
  • Phase III Transplant rejection
  • Discontinued Reperfusion injury; Septic shock; Vascular disorders

Most Recent Events

  • 25 Jul 2017 Launched for Hereditary angioedema (In adolescents, Prevention, In adults) in USA (SC)
  • 22 Jun 2017 Phase-III clinical trials in Transplant rejection (Prevention) in USA (SC) (IV) (NCT03221842)
  • 22 Jun 2017 Phase-III clinical trials in Transplant rejection (Prevention) in Spain (SC), (IV) (EudraCT2017-000348-17)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top